A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma

Finotello, Riccardo; Henriques, Joaquim; Sabattini, Silvia; Stefanello, Damiano; Felisberto, Ricardo; Pizzoni, S.; Ferrari, R.; Marconato, Laura

doi:10.1111/vco.12193

Cited by 33 publications

(69 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thalidomide has gained recent interest in veterinary oncology taking part into metronomic strategies . The anti‐angiogenic effect of thalidomide is believed to occur through the inhibition of VEGF, bFGF and TNF‐a .…”

Section: Discussionmentioning

confidence: 99%

The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma

Rossi

Sabattini

Vascellari

et al. 2018

Vet Comparative Oncology

Self Cite

View full text Add to dashboard Cite

In dogs, inflammatory mammary carcinoma is a clinicopathological entity characterized by rapid progression and aggressive behavior from onset of disease. Reported median survival time is short, with no effective treatment options. The aims of this prospective, noncontrolled clinical trial were to investigate outcome variables and safety profile of toceranib, thalidomide and piroxicam with or without hypofractionated radiation therapy in dogs with measurable histologically confirmed inflammatory mammary carcinoma that underwent a complete staging. Eighteen dogs were enrolled: 14 received medical treatment, and 4 were treated with hypofractionated radiation therapy and medical therapy. Overall, median time to progression was 34 days and median survival time was 109 days. In dogs treated with medical therapy, overall response rate was 21%, and clinical benefit rate (CBR) was 64%; median time to progression was 28 days and median survival time was 59 days. In dogs receiving medical therapy and undergoing radiation therapy, overall response rate and clinical benefit rate were 100%, with significantly longer time to progression (156 days) and survival time (180 days). Overall, treatment was well tolerated, with mild gastrointestinal and dermatological adverse events. Although the optimal treatment to this disease remains uncertain, the current approach consisting of systemic anti-angiogenic drugs with or without hypofractionated radiation therapy, provided clinical benefit in a significant proportion of dogs and should, therefore, be further explored.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma

Rossi

Sabattini

Vascellari

et al. 2018

Vet Comparative Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the study performed by Finotello et al . () in which thalidomide was utilised in 70% of the patients along with MC cyclophosphamide and a NSAID, there was improvement in the PFS and OST. Thalidomide has known anti‐angiogenic properties (Rebuck & Fish ).…”

Section: Discussionmentioning

confidence: 99%

“…Finotello et al . () also included dogs with non‐visceral HSA ( i.e . subcutaneous HSA and osseous HSA) which may have contributed to the overall improved survival times found in their study as there are documented survival differences based on the primary tumour location (Ward et al .…”

Section: Discussionmentioning

confidence: 99%

“…Another study found dogs with HSA treated with a metronomic protocol consisting of cyclophosphamide, a NSAID (non‐steroidal anti‐inflammatory drug), ±thalidomide after maximum tolerated dose (MTD) doxorubicin‐based chemotherapy had improved median survival times (not reached versus 168 days) and time to metastasis (not reached versus 150 days) (Finotello et al . ).…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma

Alexander¹,

Cronin²,

Silver³

et al. 2018

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…Despite continuous progress in elucidating the oncogenic mechanism of canine HSA along with identification of potential therapeutic targets, there is still no effective therapeutic strategy. The survival time following splenectomy for dogs with splenic HSA is extremely short; even when splenectomy and chemotherapy are used in combination, the survival time is only about 6 months . One of the main contributions to this poor prognosis in the high rate of metastasis for canine HSA; thus, systemic therapy targeting the metastatic lesions as well as the original tumour should be developed.…”

Section: Introductionmentioning

confidence: 99%

Tumour necrosis factor‐related apoptosis‐inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro

Goto

Owaki

Hirata

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is an apoptosis‐inducing cytokine that shows potential therapeutic value for human neoplasms, and is effective in some canine tumours; however, its potential for killing canine hemangiosarcoma (HSA) cells is unknown. Thus, we evaluated the proapoptotic effect of TRAIL in nine canine HSA cell lines. Cells (JuA1, JuB2, JuB2‐1, JuB4, Re11, Re12, Re21, Ud2 and Ud6) were cultured with three recombinant human TRAILs (rhTRAILs): TRAIL‐TEC derived from Escherichia coli, TRAIL‐TL derived from mammalian cells and isoleucine zipper recombinant human TRAIL (izTRAIL) containing an isoleucine‐zippered structure that facilitates trimerization. TRAIL‐TEC did not decrease the cell viability in any of the cell lines tested, whereas the other two rhTRAILs effectively decreased the viability of all cell lines as assessed by the WST‐1 assay. In canine HSA cells, izTRAIL induced apoptosis more effectively than TRAIL‐TL. In JuB4, Re12, and Ud6 cells, izTRAIL increased the activation of caspase‐3 and caspase‐8 and caused poly (ADP‐ribose) polymerase degradation. Moreover, izTRAIL treatment increased the proportion of Annexin V+/ Propidium iodide (PI)− apoptotic cells and nuclear fragmentation in izTRAIL‐sensitive cells. These results show that rhTRAIL can induce apoptosis in canine HSA cells, but the sensitivity of TRAIL was different depending on the cell lines. Therefore, TRAIL could be an effective therapeutic agent against canine HSA, but the specific mechanism of resistance should be determined to clarify under what conditions this treatment would be most effective.

show abstract

A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma

Cited by 33 publications

References 34 publications

The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma

The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma

The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma

Tumour necrosis factor‐related apoptosis‐inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro

Contact Info

Product

Resources

About